PK MED

Executive Summary

PK MED is a French biotechnology company founded in 2015 and based in Lyon, specializing in innovative, injectable, and biodegradable drug delivery micro-implants. The company's platform aims to create local therapies for rheumatology and cell-homing technologies to improve bone marrow transplantation outcomes. Despite being founded a decade ago, PK MED remains in early-stage development, targeting high unmet medical needs in gout flare, osteoarthritis, and hemoglobinopathies. The company's proprietary micro-implant technology offers potential advantages in sustained release and localized delivery, which could differentiate it from conventional systemic therapies. However, with no disclosed pipeline details or funding history publicly available, PK MED appears to be operating in a highly competitive space with significant technical and regulatory hurdles ahead.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate enters preclinical development for gout flare indication50% success
• Q1 2027Announcement of Series A or seed financing round60% success
• Q2 2027Publication of proof-of-concept data for micro-implant in osteoarthritis45% success